Latest Protein A Stories
In the future, artifical cells may produce complex protein structures on demand For years, scientists around the world have dreamed of building a complete, functional, artificial cell. Though this vision is still a distant blur on the horizon, many are making progress on various fronts. Prof. Roy Bar-Ziv and his research team in the Weizmann Institute’s Materials and Interfaces Department recently took a significant step in this direction when they created a two-dimensional, cell-like...
Scientists at The Scripps Research Institute have made an important discovery about the internal programming of B cells, the immune cells that make antibodies against infections. The finding opens the way for the development of vaccines that can work more efficiently and hints at therapies for conditions in which B cells cause harm—such as the autoimmune disease lupus erythymatosus, severe allergies, and B-cell lymphomas. The discovery reveals that B cells produce special proteins to...
Speed can save lives – especially in the case of blood poisoning. The more quickly and directly doctors recognize and treat sepsis, the greater the patient’s chances of survival. With the help of a new biochip, physicians will now be able to analyze blood within their own practice. Is the patient suffering from blood poisoning? To answer this question, the doctor draws a blood sample and sends it to a central laboratory for testing. This takes up valuable time, which could cost the...
New research suggests that some patients develop a potentially deadly blood infection from their implanted cardiac devices because bacterial cells in their bodies have gene mutations that allow them to stick to the devices. Patients with implants can develop infections because of a biofilm of persistent bacterial bugs on the surfaces of their devices. Researchers found that some strains of the bacteria, Staphylococcus aureus, have just a few genetic variants in the proteins on their...
PRINCETON, N.J., June 23 /PRNewswire/ -- BioWa, Inc. announced today that it has entered into two agreements with GlaxoSmithKline (GSK). BioWa and GSK have amended their existing 2007 arrangement in order to provide GSK with extended access to BioWa's POTELLIGENT® Technology platform for the research, development and commercialization of their antibody therapeutics with enhanced antibody-dependent cellular cytotoxicity (ADCC). The second license agreement provides GSK with access to...
WALTHAM, Mass., Feb. 3 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office for a patent covering a recombinant form of Protein A which is identical in structure to the commercial form of Protein A from Staphylococcus aureus which is used in the production of many of the world's approved monoclonal antibodies. The patent, which will remain in force until 2028, covers a new...
The same molecules, known as type I IFNs, that are central to the protective immune response following infection with a virus, can markedly increase the severity of pneumonia caused by the bacterium Staphylococcus aureus, which is becoming a major health problem due to the emergence of methicillin-resistant (MRSA) strains.Alice Prince of Columbia University College of Physicians and Surgeons, New York, NY and colleagues have now determined that Staphylococcus aureus bacteria induce the...
WALTHAM, Mass., Feb. 12 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN), a global leader in the manufacture of recombinant Protein A products, announced today that the Company has received ISO 9001:2000 (ISO) certification, the international standard for best practices for manufacturing and quality systems. ISO certification was granted for the quality management system supporting the manufacture of products and related services underlying its Protein A business. Repligen...
PRINCETON, N.J., July 16 /PRNewswire-FirstCall/ -- BioWa, Inc. and Medarex, Inc. announced today that they have entered into a license agreement which provides Medarex with the first ever access to BioWa's COMPLEGENT(TM) Technology for enhancing the complement-dependent cytotoxicity (CDC) of select Medarex therapeutic antibodies. The license grants Medarex non-exclusive rights to research, develop and commercialize therapeutic antibodies based on COMPLEGENT(TM) Technology for an...
Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation of the joints, which gradually erodes the cartilage and bone. The agents of destruction include inflammatory cells, cytokines, and protein-degrading enzymes known as matrix metalloproteinases (MMPs). The vicious cycle begins when inflammatory cells infiltrate the tissue lining the joints and consume excess oxygen. In addition to unleashing MMPs, the oxidative stress provokes non-enzymatic glycation "“ a...
